Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 26 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cytokine Storm Clear all
Completed Phase 2 Interventional Results available

Gulf War Illness Nasal Irrigation Study

NCT01700725
View directory record Official record
Conditions
Persian Gulf Syndrome, Chronic Sinusitis, Fatigue, Acute Sinusitis
Interventions
Nasal Irrigation - Saline, Nasal Irrigation - Xylitol
Other · Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
35 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 20, 2019 · Synced Jul 21, 2026, 11:47 AM EDT
Completed Not applicable Interventional

UNITE Study (UMN-SW) for COVID-19

NCT04854798
View directory record Official record
Conditions
Covid19, Cytokine Storm, Inflammation
Interventions
Splenic Ultrasound
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Burnsville, Minnesota • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Jul 21, 2026, 11:47 AM EDT
Terminated Phase 2 Interventional

Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).

NCT04433546
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Coronavirus, Hypoxic Respiratory Failure, Hypoxemic Respiratory Failure, Respiratory Complication, Respiratory Insufficiency, Cardiac Dysfunction, Pneumonia, Pulmonary Edema, Pulmonary Inflammation, Respiratory Failure, Cytokine Storm, COVID 19, SARS-CoV-2, Cardiac Event, Cardiac Complication, Cardiac Failure, Cardiac Infarct
Interventions
Pemziviptadil (PB1046), Low Dose (10 mg) Control
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
4
States / cities
Jacksonville, Florida • Sarasota, Florida • Kansas City, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Jul 21, 2026, 11:47 AM EDT
Terminated Phase 2 Interventional Results available

Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19

NCT04365985
View directory record Official record
Conditions
COVID-19, Acute Respiratory Distress Syndrome, Severe Acute Respiratory Syndrome (SARS), Coronavirus Infections
Interventions
Naltrexone, Ketamine, Placebo
Drug · Other
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Jul 21, 2026, 11:47 AM EDT
Terminated Phase 1Phase 2 Interventional

RAPA-501-Allo Therapy of COVID-19-ARDS

NCT04482699
View directory record Official record
Conditions
Severe COVID-19 Disease
Interventions
RAPA-501-Allo off-the-shelf Therapy of COVID-19, Placebo
Biological · Other
Lead sponsor
Rapa Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Jul 21, 2026, 11:47 AM EDT
Completed Not applicable Interventional

UNITE Study (UMN-GE) for COVID-19

NCT04701489
View directory record Official record
Conditions
Covid19, Cytokine Storm, Inflammation
Interventions
Splenic ultrasound
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Jul 21, 2026, 11:47 AM EDT
Recruiting No phase listed Observational

Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE Study

NCT06339177
View directory record Official record
Conditions
Lymphohistiocytosis, Hemophagocytic, Secondary Hemophagocytic Lymphohistiocytosis, Macrophage Activation Syndrome, Hyperinflammatory Syndromes
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 120 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
2
States / cities
Bethesda, Maryland • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Jul 21, 2026, 11:47 AM EDT
Terminated Phase 2 Interventional Results available

Etoposide in Patients With COVID-19 Infection

NCT04356690
View directory record Official record
Conditions
COVID-19
Interventions
Etoposide
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Jul 21, 2026, 11:47 AM EDT
Not listed Phase 2 Interventional

Selenium as a Potential Treatment for Moderately-ill, Severely-ill, and Critically-ill COVID-19 Patients.

NCT04869579
View directory record Official record
Conditions
Covid19
Interventions
Selenium (as Selenious Acid), Placebo
Drug · Other
Lead sponsor
CHRISTUS Health
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Longview, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Jul 21, 2026, 11:47 AM EDT
Terminated Phase 3 Interventional

MSCs in COVID-19 ARDS

NCT04371393
View directory record Official record
Conditions
Mesenchymal Stromal Cells, Remestemcel-L, Acute Respiratory Distress Syndrome, COVID
Interventions
Remestemcel-L, Placebo
Biological · Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
21
States / cities
Gilbert, Arizona • Los Angeles, California • Stanford, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2022 · Synced Jul 21, 2026, 11:47 AM EDT
Completed Phase 2 Interventional Results available

Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19)

NCT04466098
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, ARDS (Moderate or Severe), COVID-19 Pneumonia
Interventions
Mesenchymal stromal cells, Placebo
Biological · Other
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Minneapolis, Minnesota • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Jul 21, 2026, 11:47 AM EDT
Completed Phase 3 Interventional Results available

Early Treatment of Cytokine Storm Syndrome in Covid-19

NCT04362111
View directory record Official record
Conditions
Cytokine Storm, COVID-19
Interventions
Anakinra, Normal saline
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Jul 21, 2026, 11:47 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Fluoxetine to Reduce Intubation and Death After COVID19 Infection

NCT04377308
View directory record Official record
Conditions
COVID-19, Cytokine Storm
Interventions
Fluoxetine
Drug
Lead sponsor
University of Toledo Health Science Campus
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Jul 21, 2026, 11:47 AM EDT
Withdrawn Phase 2 Interventional

Anakinra, COVID-19, Cytokine Storm

NCT04603742
View directory record Official record
Conditions
Covid19, Cytokine Storm, Mechanical Ventilation Complication
Interventions
Anakinra, 0.9% Saline
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 89 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 24, 2022 · Synced Jul 21, 2026, 11:47 AM EDT
Not listed No phase listed Observational

Cytokine and Eicosanoid Mediators in Coronavirus Disease 2019 (COVID-19)

NCT04452942
View directory record Official record
Conditions
COVID-19
Interventions
Not listed
Lead sponsor
EicOsis Human Health Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Jul 21, 2026, 11:47 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

INB03 for the Treatment of Pulmonary Complications From COVID-19

NCT04370236
View directory record Official record
Conditions
COVID-19
Interventions
INB03, Placebo
Drug
Lead sponsor
Inmune Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
9
States / cities
Jonesboro, Arkansas • Louisville, Kentucky • Kosciusko, Mississippi + 4 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Jul 21, 2026, 11:47 AM EDT
Not listed Phase 3 Interventional

Best Supportive Care With or Without Low Dose Whole Lung Radiation Therapy for the Treatment of COVID-19

NCT04433949
View directory record Official record
Conditions
Pneumonia, Severe Acute Respiratory Syndrome, Symptomatic COVID-19 Infection Laboratory-Confirmed
Interventions
Best Practice, Low Dose Radiation Therapy
Other · Radiation
Lead sponsor
Emory University
Other
Eligibility
50 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Jul 21, 2026, 11:47 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)

NCT04351243
View directory record Official record
Conditions
COVID-19
Interventions
Gimsilumab, Placebo
Drug
Lead sponsor
Kinevant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
33
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced Jul 21, 2026, 11:47 AM EDT
Terminated Phase 2 Interventional Results available

A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19

NCT04415073
View directory record Official record
Conditions
Coronavirus, COVID, ARDS, Cytokine Storm, Cytokine Release Syndrome
Interventions
SNDX-6352, Placebo
Drug
Lead sponsor
Syndax Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
2
States / cities
Scottsdale, Arizona • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Jul 21, 2026, 11:47 AM EDT
Terminated Phase 3 Interventional Results available

Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)

NCT04377620
View directory record Official record
Conditions
COVID-19
Interventions
Placebo, Ruxolitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
35
States / cities
Scottsdale, Arizona • San Diego, California • Washington D.C., District of Columbia + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Jul 21, 2026, 11:47 AM EDT
Terminated Phase 2 Interventional

A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients

NCT04458298
View directory record Official record
Conditions
COVID-19
Interventions
OP-101, Placebo
Drug
Lead sponsor
Ashvattha Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
8
States / cities
Loma Linda, California • Fort Lauderdale, Florida • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2023 · Synced Jul 21, 2026, 11:47 AM EDT
Withdrawn Phase 2 Interventional

RepurpoSing Old Drugs TO SuppRess a Modern Threat: COVID-19 STORM

NCT04433078
View directory record Official record
Conditions
Cytokine Storm, SARS-CoV-2
Interventions
Doxycycline, Placebo
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 18, 2021 · Synced Jul 21, 2026, 11:47 AM EDT
Terminated Phase 2 Interventional Results available

Prazosin to Prevent COVID-19 (PREVENT-COVID Trial)

NCT04365257
View directory record Official record
Conditions
COVID-19
Interventions
Prazosin, Standard of care
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
45 Years to 85 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 9, 2023 · Synced Jul 21, 2026, 11:47 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of CTO1681 for the Prevention and Treatment of CRS in DLBCL Patients Receiving CAR T-Cell Therapy

NCT05905328
View directory record Official record
Conditions
Cytokine Release Syndrome
Interventions
CTO1681 10 μg, CTO1681 20 μg, CTO1681 30 μg
Drug
Lead sponsor
CytoAgents, Inc.
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
Orange, California • Augusta, Georgia • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Jul 21, 2026, 11:47 AM EDT